The Role of Fc Receptors in HIV Prevention and Therapy

Overview

Journal Immunol Rev

Specialties Allergy & Immunology
General Surgery

Date 2015 Oct 27

PMID 26497529

Citations 28

Authors

Austin W Boesch

Eric P Brown

Margaret E Ackerman

Affiliations

Soon will be listed here.

Abstract

Over the past decade, a wealth of experimental evidence has accumulated supporting the importance of Fc receptor (FcR) ligation in antibody-mediated pathology and protection in many disease states. Here we present the diverse evidence base that has accumulated as to the importance of antibody effector functions in the setting of HIV prevention and therapy, including clinical correlates, genetic associations, viral evasion strategies, and a rapidly growing number of compelling animal model experiments. Collectively, this work identifies antibody interactions with FcR as important to both therapeutic and prophylactic strategies involving both passive and active immunity. These findings mirror those in other fields as investigators continue to work toward identifying the right antibodies and the right effectors to be present at the right sites at the right time.

Citing Articles

Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Boomgarden A, Upadhyay C Vaccines (Basel). 2025; 13(2).

PMID: 40006695 PMC: 11860913. DOI: 10.3390/vaccines13020148.

Polyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression.

Grobben M, Bakker M, Schriek A, Levels L, Umotoy J, Tejjani K PLoS Pathog. 2024; 20(12):e1012739.

PMID: 39661636 PMC: 11634010. DOI: 10.1371/journal.ppat.1012739.

Mapping the interplay between NK cells and HIV: therapeutic implications.

Anderko R, Mailliard R J Leukoc Biol. 2023; 113(2):109-138.

PMID: 36822173 PMC: 10043732. DOI: 10.1093/jleuko/qiac007.

Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA.

Cottignies-Calamarte A, Tudor D, Bomsel M Front Immunol. 2023; 14:1037033.

PMID: 36817447 PMC: 9933243. DOI: 10.3389/fimmu.2023.1037033.

FCGR3A gene duplication, FcγRIIb-232TT and FcγRIIIb-HNA1a associate with an increased risk of vertical acquisition of HIV-1.

Ebonwu J, Lassauniere R, Paximadis M, Strehlau R, Gray G, Kuhn L PLoS One. 2022; 17(9):e0273933.

PMID: 36084039 PMC: 9462732. DOI: 10.1371/journal.pone.0273933.

References

Gupta S, Gach J, Becerra J, Phan T, Pudney J, Moldoveanu Z . The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog. 2013; 9(11):e1003776. PMC: 3836734. DOI: 10.1371/journal.ppat.1003776. View

Teeling J, Mackus W, Wiegman L, van den Brakel J, Beers S, French R . The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006; 177(1):362-71. DOI: 10.4049/jimmunol.177.1.362. View

van den Bremer E, Beurskens F, Voorhorst M, Engelberts P, de Jong R, van der Boom B . Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation. MAbs. 2015; 7(4):672-80. PMC: 4622059. DOI: 10.1080/19420862.2015.1046665. View

Woof J, Russell M . Structure and function relationships in IgA. Mucosal Immunol. 2011; 4(6):590-7. DOI: 10.1038/mi.2011.39. View

Yada A, Ebihara S, Matsumura K, Endo S, Maeda T, Nakamura A . Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake. Cell Immunol. 2003; 225(1):21-32. DOI: 10.1016/j.cellimm.2003.09.008. View

Chojnacki J, Staudt T, Glass B, Bingen P, Engelhardt J, Anders M . Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. Science. 2012; 338(6106):524-8. DOI: 10.1126/science.1226359. View

Dugast A, Stamatatos L, Tonelli A, Suscovich T, Licht A, Mikell I . Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur J Immunol. 2014; 44(10):2925-37. PMC: 4311770. DOI: 10.1002/eji.201344305. View

Fahrbach K, Malykhina O, Stieh D, Hope T . Differential binding of IgG and IgA to mucus of the female reproductive tract. PLoS One. 2013; 8(10):e76176. PMC: 3788792. DOI: 10.1371/journal.pone.0076176. View

Chung A, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S . Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med. 2014; 6(228):228ra38. DOI: 10.1126/scitranslmed.3007736. View

10.

Yates N, Liao H, Fong Y, deCamp A, Vandergrift N, Williams W . Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014; 6(228):228ra39. PMC: 4116665. DOI: 10.1126/scitranslmed.3007730. View

11.

Kono H, Kyogoku C, Suzuki T, Tsuchiya N, Honda H, Yamamoto K . FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet. 2005; 14(19):2881-92. DOI: 10.1093/hmg/ddi320. View

12.

Vidarsson G, Stemerding A, Stapleton N, Spliethoff S, Janssen H, Rebers F . FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood. 2006; 108(10):3573-9. DOI: 10.1182/blood-2006-05-024539. View

13.

Rolland M, Edlefsen P, Larsen B, Tovanabutra S, Sanders-Buell E, Hertz T . Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012; 490(7420):417-20. PMC: 3551291. DOI: 10.1038/nature11519. View

14.

Bonsignori M, Pollara J, Moody M, Alpert M, Chen X, Hwang K . Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol. 2012; 86(21):11521-32. PMC: 3486290. DOI: 10.1128/JVI.01023-12. View

15.

Barouch D, Whitney J, Moldt B, Klein F, Oliveira T, Liu J . Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013; 503(7475):224-8. PMC: 4017780. DOI: 10.1038/nature12744. View

16.

Qiao X, He B, Chiu A, Knowles D, Chadburn A, Cerutti A . Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol. 2006; 7(3):302-10. DOI: 10.1038/ni1302. View

17.

Roy N, Chan J, Lambele M, Thali M . Clustering and mobility of HIV-1 Env at viral assembly sites predict its propensity to induce cell-cell fusion. J Virol. 2013; 87(13):7516-25. PMC: 3700267. DOI: 10.1128/JVI.00790-13. View

18.

Shibata-Koyama M, Iida S, Misaka H, Mori K, Yano K, Shitara K . Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol. 2009; 37(3):309-21. DOI: 10.1016/j.exphem.2008.11.006. View

19.

Choi I, Chung A, Suscovich T, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S . Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees. PLoS Comput Biol. 2015; 11(4):e1004185. PMC: 4395155. DOI: 10.1371/journal.pcbi.1004185. View

20.

Cocklin S, Schmitz J . The role of Fc receptors in HIV infection and vaccine efficacy. Curr Opin HIV AIDS. 2014; 9(3):257-62. PMC: 4120665. DOI: 10.1097/COH.0000000000000051. View